Clinical utility of the risperidone formulations in the management of schizophrenia

Vishal Madaan, Durga P. Bestha, Venkata Kolli, Saurabh Jauhari, Roger C. Burket

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs) but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use.

Original languageEnglish (US)
Pages (from-to)611-620
Number of pages10
JournalNeuropsychiatric Disease and Treatment
Volume7
Issue number1
StatePublished - Nov 16 2011

Fingerprint

Risperidone
Schizophrenia
Antipsychotic Agents
Placebos
Hyperprolactinemia
Injections
Medication Adherence
Safety

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Clinical utility of the risperidone formulations in the management of schizophrenia. / Madaan, Vishal; Bestha, Durga P.; Kolli, Venkata; Jauhari, Saurabh; Burket, Roger C.

In: Neuropsychiatric Disease and Treatment, Vol. 7, No. 1, 16.11.2011, p. 611-620.

Research output: Contribution to journalReview article

Madaan, Vishal ; Bestha, Durga P. ; Kolli, Venkata ; Jauhari, Saurabh ; Burket, Roger C. / Clinical utility of the risperidone formulations in the management of schizophrenia. In: Neuropsychiatric Disease and Treatment. 2011 ; Vol. 7, No. 1. pp. 611-620.
@article{8e1892498caa41228e7f4eabbbedf44e,
title = "Clinical utility of the risperidone formulations in the management of schizophrenia",
abstract = "Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs) but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use.",
author = "Vishal Madaan and Bestha, {Durga P.} and Venkata Kolli and Saurabh Jauhari and Burket, {Roger C.}",
year = "2011",
month = "11",
day = "16",
language = "English (US)",
volume = "7",
pages = "611--620",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Clinical utility of the risperidone formulations in the management of schizophrenia

AU - Madaan, Vishal

AU - Bestha, Durga P.

AU - Kolli, Venkata

AU - Jauhari, Saurabh

AU - Burket, Roger C.

PY - 2011/11/16

Y1 - 2011/11/16

N2 - Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs) but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use.

AB - Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs) but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use.

UR - http://www.scopus.com/inward/record.url?scp=80955122614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80955122614&partnerID=8YFLogxK

M3 - Review article

VL - 7

SP - 611

EP - 620

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 1

ER -